GRAIL/$GRAL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GRAIL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Ticker
$GRAL
Sector
Primary listing
Employees
1,000
Headquarters
Website
GRAIL Metrics
BasicAdvanced
$2.9B
-
-$13.06
-
-
Price and volume
Market cap
$2.9B
52-week high
$103.00
52-week low
$12.76
Average daily volume
1.1M
Financial strength
Current ratio
9.228
Quick ratio
8.764
Long term debt to equity
2.094
Total debt to equity
2.686
Profitability
EBITDA (TTM)
-407.206
Gross margin (TTM)
-56.53%
Net profit margin (TTM)
-329.86%
Operating margin (TTM)
-420.35%
Effective tax rate (TTM)
26.01%
Revenue per employee (TTM)
$130,000
Management effectiveness
Return on assets (TTM)
-11.81%
Return on equity (TTM)
-17.68%
Valuation
Price to revenue (TTM)
20.138
Price to book
1.24
Price to tangible book (TTM)
7.28
Price to free cash flow (TTM)
-7.274
Free cash flow yield (TTM)
-13.75%
Free cash flow per share (TTM)
-10.965
Growth
Revenue change (TTM)
22.37%
Earnings per share change (TTM)
-85.93%
What the Analysts think about GRAIL
Analyst ratings (Buy, Hold, Sell) for GRAIL stock.
Bulls say / Bears say
The PATHFINDER 2 study from GRAIL showed higher cancer detection rates than the initial trial, with improvements in positive predictive value, 99.5% specificity, and 88% accuracy in identifying the cancer’s origin, solidifying the test’s clinical credibility (Investing.com).
GRAIL had $677.9 million in cash at the end of the first quarter of 2025, providing enough funding through 2028 to support further commercial expansion and ongoing study submissions for FDA approval (PR Newswire).
Canaccord Genuity keeps a Buy rating on GRAIL, citing its head start in multi-cancer early detection and projecting that achieving regulatory and reimbursement milestones could lift annual test volumes to two million and annual revenue to $800 million by 2032 (Barron’s).
GRAIL posted a net loss of $114.0 million in the second quarter of 2025, with adjusted EBITDA at $(78.3) million, highlighting ongoing unprofitability despite revenue growth (PR Newswire).
The Galleri test does not yet have FDA Premarket Approval and is not widely covered by insurance, limiting its uptake until these regulatory and reimbursement hurdles are overcome (Barron’s).
Rising competition from Guardant Health’s Shield test and Exact Sciences’ Cancerguard test poses a threat to Galleri’s share of the large and profitable multi-cancer screening market (Barron’s).
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
GRAIL Financial Performance
Revenues and expenses
GRAIL Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GRAIL stock?
GRAIL (GRAL) has a market cap of $2.9B as of October 23, 2025.
What is the P/E ratio for GRAIL stock?
The price to earnings (P/E) ratio for GRAIL (GRAL) stock is 0 as of October 23, 2025.
Does GRAIL stock pay dividends?
No, GRAIL (GRAL) stock does not pay dividends to its shareholders as of October 23, 2025.
When is the next GRAIL dividend payment date?
GRAIL (GRAL) stock does not pay dividends to its shareholders.
What is the beta indicator for GRAIL?
GRAIL (GRAL) does not currently have a Beta indicator.